Andrew K. Balo Sells 5,000 Shares of DexCom, Inc. (DXCM) Stock
DexCom, Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $124.25, for a total transaction of $621,250.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Andrew K. Balo also recently made the following trade(s):
- On Monday, July 16th, Andrew K. Balo sold 5,000 shares of DexCom stock. The shares were sold at an average price of $99.56, for a total transaction of $497,800.00.
Shares of DXCM stock opened at $130.96 on Friday. DexCom, Inc. has a 12 month low of $42.62 and a 12 month high of $131.10. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.62 and a current ratio of 4.89. The company has a market cap of $10.90 billion, a price-to-earnings ratio of -225.79 and a beta of 0.05.
DXCM has been the subject of several research reports. BTIG Research restated a “hold” rating on shares of DexCom in a research report on Thursday, May 3rd. Oppenheimer upped their price objective on shares of DexCom from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Thursday, May 3rd. Raymond James raised shares of DexCom from a “market perform” rating to an “outperform” rating in a research report on Monday, July 2nd. BMO Capital Markets increased their price objective on DexCom to $112.00 and gave the stock an “outperform” rating in a report on Tuesday, July 10th. Finally, Piper Jaffray Companies increased their price objective on DexCom to $116.00 and gave the stock an “overweight” rating in a report on Tuesday, June 12th. Two analysts have rated the stock with a sell rating, six have given a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $103.19.
A number of hedge funds have recently made changes to their positions in DXCM. Rockefeller Capital Management L.P. acquired a new stake in shares of DexCom in the first quarter worth $67,132,000. Point72 Asset Management L.P. grew its stake in shares of DexCom by 429.3% in the first quarter. Point72 Asset Management L.P. now owns 979,175 shares of the medical device company’s stock worth $72,616,000 after acquiring an additional 794,175 shares during the last quarter. Morgan Stanley grew its stake in shares of DexCom by 16.3% in the second quarter. Morgan Stanley now owns 5,028,874 shares of the medical device company’s stock worth $477,644,000 after acquiring an additional 705,072 shares during the last quarter. Neuberger Berman Group LLC grew its stake in shares of DexCom by 501.9% in the first quarter. Neuberger Berman Group LLC now owns 637,416 shares of the medical device company’s stock worth $47,271,000 after acquiring an additional 531,513 shares during the last quarter. Finally, Victory Capital Management Inc. grew its stake in shares of DexCom by 67,520.1% in the second quarter. Victory Capital Management Inc. now owns 494,303 shares of the medical device company’s stock worth $46,948,000 after acquiring an additional 493,572 shares during the last quarter.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Further Reading: What is the Book Value of a Share?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.